Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update
March 14, 2022 16:30 ET | Vor Biopharma
Initial clinical data for Vor Bio’s engineered HSC candidate VOR33 expected in 2H 2022New program VCAR33ALLO using healthy donor-derived T cells IND submission expected in 1H 2023Cash runway extended...
Vor-Wordmark-RGB-FullColor-070920.png
Vor to Participate in Three Upcoming Investor Conferences
February 28, 2022 08:00 ET | Vor Biopharma
CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that members of its senior management team will...
Vor-Wordmark-RGB-FullColor-070920.png
Vor to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
February 11, 2022 08:00 ET | Vor Biopharma
CAMBRIDGE, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Dr. Robert Ang, Vor’s President and Chief...
Vor-Wordmark-RGB-FullColor-070920.png
Vor to Participate in Two Upcoming Investor Conferences
January 04, 2022 08:00 ET | Vor Biopharma
CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that members of its senior management team will...
Vor-Wordmark-RGB-FullColor-070920.png
Vor to Participate in the JMP Securities Hematology and Oncology Summit
November 29, 2021 08:00 ET | Vor Biopharma
CAMBRIDGE, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Dr. Robert Ang, Vor’s President and Chief...
Vor-Wordmark-RGB-FullColor-070920.png
Vor to Participate in Piper Sandler 33rd Virtual Annual Healthcare Conference
November 19, 2021 16:01 ET | Vor Biopharma
CAMBRIDGE, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Dr. Robert Ang, Vor’s President and Chief...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Reports Third Quarter 2021 Financial Results and Provides Company Update
November 10, 2021 16:10 ET | Vor Biopharma
VOR33 on track with initial clinical data expected in the first half of 2022Announced pipeline expansion with first multi-targeted Treatment System simultaneously targeting CD33 and CLL-1 for AML ...
Vor-Wordmark-RGB-FullColor-070920.png
Vor to Present New Data on its Cell and Genome Engineering Platform at SITC Annual Meeting
November 09, 2021 08:30 ET | Vor Biopharma
CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the presentation of new data from its novel...
Vor-Wordmark-RGB-FullColor-070920.png
Vor to Participate in Two Upcoming Investor Conferences
November 08, 2021 08:00 ET | Vor Biopharma
CAMBRIDGE, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell and genome engineering company, today announced that Robert Ang, M.B.B.S., MBA, Vor’s President and Chief...
Vor-Wordmark-RGB-FullColor-070920.png
Vor to Present New Platform and Preclinical Data at ASH
November 04, 2021 09:15 ET | Vor Biopharma
Knock out of CD123 or CLL-1 by CRISPR-Cas9 from Human Hematopoietic Stem Cells Maintains Hematopoietic Function and is Resistant to Targeted TherapiesMultiplex Engineering of Human CD34+ HSPCs Enables...